- Home
- DOUG vs INBX Comparison
DOUG vs INBX Comparison
Compare DOUG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | INBX |
|---|---|---|
| Founded | 1911 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.3M | 999.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | DOUG | INBX |
|---|---|---|
| Price | $1.71 | $116.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | 476.7K | ★ 563.4K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $955,578,000.00 | $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $1.53 | $12.80 |
| 52 Week High | $3.20 | $155.29 |
Technical Indicators
Market Signals| Indicator | DOUG | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 53.53 |
| Support Level | $1.55 | $69.30 |
| Resistance Level | $1.84 | $155.29 |
| Average True Range (ATR) | 0.13 | 12.87 |
| MACD | -0.03 | -2.65 |
| Stochastic Oscillator | 7.07 | 32.55 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.